Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
How the UK’s rollback of banking regulations could risk another financial crisis 
Infosys Shares Drop Amid Earnings Quality Concerns 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
European Stocks Rally on Chinese Growth and Mining Merger Speculation 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Investors Brace for Market Moves as Trump Begins Second Term 
Apple Downgraded by Jefferies Amid Weak iPhone Sales and AI Concerns 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Tempus AI Inc (NASDAQ:TEM) shares surged over 18% to $41.62 in after-hours trading following a disclosure by former House Speaker Nancy Pelosi. Pelosi revealed in a recent filing that she had purchased 50 call options on the artificial intelligence-focused precision medicine firm. The options, priced between $50,000 and $100,000, have a $20 strike price and expire on January 16, 2026.
Pelosi’s disclosure also included call options in tech giants Alphabet Inc (NASDAQ:GOOGL), NVIDIA Corporation (NASDAQ:NVDA), and Amazon.com Inc (NASDAQ:AMZN).
The rally comes despite Tempus being down about 12% since its public listing in June 2024. The stock faced pressure last week when a major shareholder sold $33.1 million worth of shares, even after Tempus reported strong 2024 earnings. However, the company flagged a slowdown in contract research organization revenues, sparking some investor caution.
Sentiment around Tempus has turned highly bullish on trading platforms like Stocktwits, with discussions about the stock spiking after Pelosi’s disclosure. The platform reported increased interest and optimism, which contributed to the stock’s strong rally.
Tempus leverages artificial intelligence technology for precision medicine applications, and its growth potential continues to attract attention from prominent investors. This latest move by Pelosi, a well-known and closely watched figure in the investment community, has added momentum to the stock, drawing increased scrutiny from retail and institutional investors alike.
As interest in AI and precision medicine grows, Tempus is positioned as a key player, gaining visibility and market attention.
